3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasms
1
Melanoma
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Carcinoma
1
Interventions
pembrolizumab
8
Nivolumab
4
fludarabine
2
Cyclophosphamide
2
sonidegib
1
obinutuzumab
1
methyl 5-aminolevulinate
1
lutetium Lu 177 dotatate
1
fludarabine phosphate
1
durvalumab
1
daromun
1
cabozantinib
1
avelumab
1
atezolizumab
1
advexin
1
Tomography, Optical Coherence
1
Therapeutics
1
Taxes
1
Specimen Handling
1
Radiotherapy
1
ProMune
1
Pemetrexed
1
Paclitaxel
1
Oncolytic Virotherapy
1
Mesna
1
Magnetic Resonance Spectroscopy
1
MAPRE1 protein, human
1
Lutetium-177
1
Interleukin-2
1
HhAntag691
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
MAPRE1 protein, human
×
Dermatologic
×
Clear all
NCT04349436
2026-04-22
ARTACUS
Replimune, Inc.
Phase 1/2
Active not recruiting
69 enrolled